Canada Markets closed

Syros Pharmaceuticals, Inc. (0S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.8364-0.1252 (-13.02%)
At close: 08:13AM CEST
Full screen
Previous Close0.9616
Open0.8364
Bid0.9030 x 0
Ask0.9062 x 0
Day's Range0.8364 - 0.8364
52 Week Range0.6436 - 4.7400
Volume250
Avg. Volume130
Market Cap51.813M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-1.3930
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.14
  • Zacks

    CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?

    CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Business Wire

    Syros to Present at JMP Securities Life Sciences Conference

    CAMBRIDGE, Mass., June 08, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 03, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).